Scientific exchange · Dr. Emiko Tanaka

17 Jan 2026 · In person · Dr. Emiko Tanaka, Uniklinik Köln · MSL James Whitfield · Vantrexa

ReviewedManualENG-0010—

Capture insight from this engagement

Location: Uniklinik Köln
Therapeutic area: Oncology
Country: Germany
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

PD-L1 testing turnaround
Chemotherapy-free first line
Brain-metastasis subgroup data

Scientific content used

VOYAGE-1 pivotal data summary

Questions raised

No questions recorded.

Notes

Scientific exchange with thoracic medical oncologist at Uniklinik Köln. Discussed pd-l1 testing turnaround, chemotherapy-free first line, brain-metastasis subgroup data.

Insights captured (1)

Capture insight

INS-0006Medium
PD-L1 testing turnaround
PD-L1 testing turnaround: request for data reported by thoracic medical oncologist (DE).
Deduplicated

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Share MI standard response

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 4
Depth of exchange: 2
Actionability: 1

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0010

Audit history (0)

All create, update and approval events for this record

No audit events in sample data